Publisher Correction: Therapies for rare diseases: therapeutic modalities, progress and challenges ahead

Nat Rev Drug Discov. 2020 Apr;19(4):291. doi: 10.1038/s41573-019-0059-7.

¹ BioPontis Alliance for Rare Diseases Foundation fup/son, Brussels, Belgium. erik@tambuyzer.be.
² BioPontis Alliance Rare Disease Foundation, Inc, Raleigh, NC, USA. erik@tambuyzer.be.
³ Byteflies, Antwerp, Belgium.
⁴ Department of Electrical, Computer, and Systems Engineering (ECSE), Case Western Reserve University, Cleveland, OH, USA.
⁵ National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.
⁶ Orphan Medicines Office, European Medicines Agency, Amsterdam, Netherlands.
⁷ Office of Orphan Products Development, Food and Drug Administration, Silver Spring, MD, USA.
⁸ Hyman, Phelps & McNamara, Washington, DC, USA.
⁹ MDUK Oxford Neuromuscular Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.
¹⁰ Hitachi Chemical Regenerative Medicine Business Sector, Allendale, NJ, USA.
¹¹ Translational Informatics Division, Department of Internal Medicine, University of New Mexico Albuquerque, Albuquerque, NM, USA.
¹² UNM Comprehensive Cancer Center, University of New Mexico Health Science Center, Albuquerque, NM, USA.
¹³ School of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland. marco.prunotto@unige.ch.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.